The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis ; volume:30 ; number:2 ; day:29 ; month:12 ; year:2015 ; pages:135-147 ; date:2.2016
CNS drugs ; 30, Heft 2 (29.12.2015), 135-147, 2.2016
- Creator
-
Hunter, Samuel F.
- Contributor
-
Bowen, James D.
Reder, Anthony T.
SpringerLink (Online service)
- DOI
-
10.1007/s40263-015-0297-0
- URN
-
urn:nbn:de:1111-2016030931941
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hunter, Samuel F.
- Bowen, James D.
- Reder, Anthony T.
- SpringerLink (Online service)
Other Objects (12)
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Fingolimod Therapy for Multiple Sclerosis
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
A randomized study to evaluate the effect of exercise on fatigue in people with relapsing–remitting multiple sclerosis treated with fingolimod
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Fingolimod Therapy for Multiple Sclerosis
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
A randomized study to evaluate the effect of exercise on fatigue in people with relapsing–remitting multiple sclerosis treated with fingolimod
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Fingolimod Therapy for Multiple Sclerosis
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
A randomized study to evaluate the effect of exercise on fatigue in people with relapsing–remitting multiple sclerosis treated with fingolimod
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal